Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by BlackRock Inc.
BlackRock Inc. raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 34,755.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,746,234 shares of the biopharmaceutical company’s stock after buying an additional 4,732,617 shares during the period. BlackRock Inc.’s holdings in Alnylam Pharmaceuticals were worth $243,242,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock worth $446,000 after buying an additional 36 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock worth $4,170,000 after buying an additional 695 shares in the last quarter. Swiss National Bank boosted its stake in shares of Alnylam Pharmaceuticals by 0.6% in the first quarter. Swiss National Bank now owns 127,700 shares of the biopharmaceutical company’s stock worth $6,545,000 after buying an additional 800 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 19.4% in the first quarter. Pacer Advisors Inc. now owns 9,517 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 1,544 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of Alnylam Pharmaceuticals by 10.0% in the fourth quarter. Macquarie Group Ltd. now owns 17,755 shares of the biopharmaceutical company’s stock valued at $665,000 after buying an additional 1,614 shares during the period. 88.96% of the stock is owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals, Inc. (ALNY) traded down 1.80% during midday trading on Tuesday, hitting $81.44. The stock had a trading volume of 732,039 shares. The company’s 50 day moving average price is $81.11 and its 200-day moving average price is $60.45. The stock’s market capitalization is $7.02 billion. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $86.92.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The business had revenue of $19 million during the quarter, compared to analysts’ expectations of $22.91 million. During the same quarter last year, the business posted ($1.21) EPS. The company’s quarterly revenue was up 160.3% on a year-over-year basis. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.19) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/08/blackrock-inc-buys-4732617-shares-of-alnylam-pharmaceuticals-inc-nasdaqalny-updated-updated-updated.html.
ALNY has been the topic of several research reports. ValuEngine upgraded shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Piper Jaffray Companies set a $116.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 24th. Credit Suisse Group reissued a “hold” rating and issued a $50.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 9th. BidaskClub raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Needham & Company LLC lifted their target price on Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the company a “buy” rating in a research note on Tuesday, June 27th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $79.79.
In other news, major shareholder Sanofi purchased 297,501 shares of the stock in a transaction on Wednesday, May 31st. The shares were acquired at an average price of $71.87 per share, for a total transaction of $21,381,396.87. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael Mason sold 9,375 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total value of $656,250.00. Following the transaction, the vice president now directly owns 5,625 shares in the company, valued at $393,750. The disclosure for this sale can be found here. Insiders sold 64,125 shares of company stock worth $4,325,000 in the last quarter. 4.30% of the stock is currently owned by company insiders.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.